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BACKGROUND: Treatment with PD-1 inhibitors can be hampered by severe auto-immune-related toxicities. Our objective was to
identify single-nucleotide polymorphisms (SNPs) in genes previously associated with auto-immunity, which are associated with
toxicities in nivolumab-treated NSCLC patients. This was in order to identify patients prone to develop severe toxicities and to gain
more insight into the underlying pathobiology.
METHODS: We analysed 322 nivolumab-treated patients and assessed the association with toxicities for seven SNPs in four genes,
which are considered contributors to PD-1-directed T-cell responses, i.e., PDCD1, PTPN11, ZAP70 and IFNG. Every SNP was tested for
its association with toxicity endpoints. Signiﬁcant associations were tested in a validation cohort.
RESULTS: A multivariable analysis in the exploration cohort showed that homozygous variant patients for PDCD1 804C>T
(rs2227981) had decreased odds for any grade treatment-related toxicities (n= 96; OR 0.4; 95% CI 0.2–1.0; p= 0.039). However, this
result could not be validated (n= 85; OR 0.9; 95% CI 0.4–1.9; p= NS).
CONCLUSIONS: Our results show that it is unlikely that the investigated SNPs have a clinical implication in predicting toxicity. A
ﬁnding, even though negative, that is considered timely and instructive towards further research in biomarker development for
checkpoint inhibitor treatments.
British Journal of Cancer (2018) 118:1296–1301; https://doi.org/10.1038/s41416-018-0074-1
INTRODUCTION
Tumours are able to escape from an effective immune response
by exploiting phenotypical and functional changes in tumour cells
as well as stromal cells that compromise inﬁltration, migration and
local activation of anti-tumour T lymphocytes.1 One of these
changes, representing a dominant escape mechanisms in some
tumours, is over-expression of the immune checkpoint pro-
grammed cell death protein 1 (PD-1) by tumour-inﬁltrating CD8-
positve T cells, and can be counteracted by nivolumab, thereby
rescuing exhausted T cells from a non-functional status.2,3
Nivolumab is an anti-PD-1 antibody that is, among others,
approved for the treatment of melanoma, non-small cell lung
cancer (NSCLC), renal cell carcinoma, microsatellite instability-high
colorectal carcinoma, and squamous cell carcinoma of the head
and neck.4–9 Approval for other indications is expected to follow in
the near future. Unfortunately, the application of anti-PD-1
blocking agents can be accompanied by severe toxicities, such
as dermatitis, hypothyroidism, colitis and pneumonitis. These
auto-immune-related adverse events can have extensive con-
sequences, such as treatment discontinuation. Markers to identify
patients who are at risk to develop such toxicities are key to
develop a more personalised treatment approach.
Germline genetic aberrations are frequently associated with
systemic toxicities as a consequence of anti-tumour agents.10
Hence, we argue that variants of genes involved in the PD-1
pathway are associated with the occurrence of PD-1-inhibitor-
induced auto-immune-related toxicities. Moreover, PD-1, its
downstream proteins SHP2 and ZAP70, and IFNγ (Fig. 1)11–13 are
already known to be involved in disorders of the immune system:
single-nucleotide polymorphisms (SNPs) in their encoding genes
(PDCD1, PTPN11, ZAP70 and IFNG) have been associated with auto-
immune syndromes14–18 and with excessive inﬂammation.19 For
example, SNPs in PDCD1 are associated with ankylosing spondy-
litis and diabetes mellitus type 1, SNPs in ZAP70 are associated
with Crohn’s disease and SNPs in PTPN11 are associated with a
more severe course of inﬂammation after gastric infection and
ulcerative colitis. Not every patient with a predisposing genotype
develops an auto-immune phenotype, but the sensitivity of the
PD-1 axis, or its activity, might be altered in those persons. When
treated with PD-(L)1 inhibiting drugs, these (asymptomatic)
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carriers of an aberrant genotype might be more prone to develop
immune related adverse events than patients with a wildtype PD-
1 axis. Hence, we hypothesised that additional PD-1 inhibition by
nivolumab would trigger auto-immunity and consequently lead to
more toxicity in patients who harbor germline genetic poly-
morphisms in the PD-1 axis. In this study, we explored a large
cohort of nivolumab-treated NSCLC patients in daily clinical
practice and studied whether patients with SNPs in the PD-1 and
PD-1-related genes experienced toxicity more (or less) frequently
or severely than other patients.
MATERIALS AND METHODS
Study design
We collected data from NSCLC patients who started nivolumab
monotherapy treatment, without other concomitant anti-cancer
agents (e.g., chemotherapy), at two large Dutch hospitals (the
Erasmus MC Cancer Institute, Rotterdam, and at the Amphia
Hospital, Breda) between July 26th 2013 and April 5th 2017.
Clinical data was collected until June 1st 2017. Patients from
whom whole blood for DNA analysis was (prospectively) collected
were included in this study (local ethics board study number MEC
02-1002). Patients were ranked based on date of treatment start,
thereafter patients were alternately allocated to an exploration
cohort or a validation cohort, each consisting of 161 patients.
Patient characteristics were collected from the hospitals
electronic patient record systems and included demographic
and clinical information (e.g., age at start of treatment, gender,
ethnicity, WHO performance status at start of treatment, previous
anti-tumour treatments, treatment interruptions, NSCLC subtype
and toxicities). WHO performance status was determined by
judgment of the clinician at the nearest time point before start of
nivolumab treatment, and was regarded as “missing” if this point
was more than 1 month before treatment start. Concomitant use
of oral or intravenous corticosteroids to resolve immune-related
toxicities was also recorded and regarded as a surrogate for
adverse events.
Adverse events from start of treatment until end of follow-up
were retracted from the patient status, and best corresponding
grade was retrieved according to National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI-CTCAE)
v4.03 if not already graded appropriately in the patient
status. Adverse events that were possibly, probably, or deﬁnitely
related to the nivolumab treatment were classiﬁed as treatment-
related adverse events. The diagnosis of hepatitis was based on
judgment of the treating clinician. An adverse event was
considered pre-existent if it was present in the same or higher
degree before treatment start, and therefore not considered as an
event.
Selection of SNPs
We selected seven SNPs in the PDCD1, PTPN11, ZAP70 and IFNG
genes for analysis (see Table 1 for details). SNPs with a reported
minor allele frequency (MAF) above 5% were included.
DNA isolation
Four hundred microliters of whole-blood specimens were
collected in EDTA tubes and DNA was extracted in a ﬁnal elution
volume of 200 μL using the MagNAPure Compact instrument
(Roche Diagnostics GmbH, Mannheim, Germany) and the Nucleic
Acid Isolation Kit I (Roche Diagnostics GmbH).
Taqman genotyping
Genotyping was performed using predesigned DME Taqman
allelic discrimination assays on the Life Technologies Taqman
7500 system (Applied Biosystems, Life Technologies Europe BV,
Bleiswijk, The Netherlands; Table 1). Each assay consisted of two
allele-speciﬁc minor groove binding (MGB) probes, labeled with
the ﬂuorescent dyes VIC and FAM. Polymerase chain reactions
(PCR) were performed in a reaction volume of 10 µL, containing
assay-speciﬁc primers, allele-speciﬁc Taqman MGB probes
(Applied Biosystems), Abgene Absolute QPCR ROx Mix (Thermo
Scientiﬁc, Life Technologies Europe BV, Bleiswijk, The Netherlands)
and genomic DNA (20 ng). The thermal proﬁle consisted of 40
cycles of denaturation at 95 °C for 20 s, annealing at 92 °C for 3 s
and extension at 60 °C for 30 s. Genotypes were scored by
measuring allele-speciﬁc ﬂuorescence using the 7500 software
v2.3 for allelic discrimination (Applied Biosystems).
MHC-I
a b
PD-L1
PD-1
PD-1
T-Cell
Tumour
+
+
+ –
–
IFN-γ
TCR
TCR
T cell activation
Distal signalling T-Cell
PLCg PI3K
SHP-2
ZAPZ0
CD3z
TCR-mediated
proximal signalling
Fig. 1 a Interaction between a tumour cell and a T cell. Tumour cells can activate T cells by presenting an antigen through major
histocompatibility complex (MHC) to the T cell receptor (TCR). Under inﬂuence of interferon-gamma (IFNγ) tumours can express Programmed-
Death ligand-1 (PD-L1), which inhibits TCR signalling by binding and activating Programmed-Death-1 (PD-1) expressed by T cells. b Proximal
PD-1 pathway signalling. Activated PD-1 recruits SHP2, which inhibits ZAP70 function. ZAP70 is an important protein in the signalling pathway
of the TCR. Complementary to its effect on ZAP70, SHP2 may also inhibit PI3K upon PD-1 activation. Both effects lead to inhibition of T cell
activation. Note: the PD-1 pathway comprises many more proteins and signal transduction pathways, but these are omitted from this ﬁgure
since they are not included in our analysis
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Statistics
Distribution of genotypes was tested for the Hardy–Weinberg
equilibrium (HWE) using the χ2 test (Table 1). Since ZAP70-32-
4127C>A was not in HWE in the validation cohort, this SNP was
excluded from further analyses. SNPs with a MAF <5% in our
cohort were also excluded from further analyses, which was the
case for PDCD1 644C>T. Linkage disequilibrium (LD) analyses were
performed using SNAP.20 Because none of the analysed SNP pairs
met our preset criteria for LD (R2 > 0.8), all SNPs were analysed
individually. For every SNP, the best ﬁtting model (that is, the
model resulting in the best association) was selected from four
models, i.e., a dominant, recessive, additive, and multiplicative
model.21 The dominant and recessive models were used to test
associations between SNPs and toxicity, steroid use, and
temporary or deﬁnitive treatment discontinuation due to toxicity
using the χ2 test or, in case one of the observed numbers was ≤10
or one of the expected numbers was <5, with Fisher’s exact test.
The additive and multiplicative models were used to test the SNPs
in logistic regression as ordinal and linear predictor variables,
respectively. If a SNP was associated with toxicity with p < 0.1, it
was entered in a multivariable logistic regression model together
with age and gender in order to avoid bias by those parameters.
Multivariable analysis was only performed in case of approxi-
mately 10 or more events per assessed variable in order to avoid
bias of the regression coefﬁcients.22 Models with a signiﬁcant
outcome in univariable or multivariable analysis in the exploration
cohort were examined in the validation cohort. SPSS software v21
(SPSS, Chicago, IL, USA) was used for the above-mentioned
analyses. A two-sided p < 0.05 was regarded as signiﬁcant and no
correction for multiple testing was applied.
RESULTS
Patient characteristics
Blood samples for DNA analysis were available for 322 NSCLC
patients in total, of whom 63% (n= 202) were male, having a mean
age at start of therapy of 65 years, and 58% (n= 188) had a WHO
performance status of 1 at start. More baseline characteristics for
both the exploration and validation cohorts are depicted in Table 2.
All characteristics were comparable between both groups (t-test).
All patients were treated with the standard dose of nivolumab at 3
mg/kg Q2W that was not changed during treatment. Median
absolute starting dose was 222mg (IQR 192–263mg) and median
duration of follow-up was 126 days (IQR 70–214 days).
Adverse events
Fifty patients (16%) had any grade ≥3 toxicity (Table 3 and
Supplementary Table S1). When analysing all-grade toxicity that
was not pre-existent, hypothyroidism or hyperthyroidism (n= 129;
40%), elevated transaminases (n= 106; 33%), and skin toxicity
Table 1. Investigated single-nucleotide polymorphisms
Gene Protein rs-number Variant Assay ID Cohort WT HET HVAR Undetermined MAF HWEa
PDCD1 PD-1 rs2227981 804C>T c__57931286_20 Exploration 50 76 34 1 45% 0.61
Validation 44 78 39 0 48% 0.70
rs2227982 644C>T c__57931287_10 Exploration 159 2 0 0 1% 0.9
Validation 161 0 0 0 0% n/a
rs10204525 *889G>A c____172862_10 Exploration 139 20 2 0 7% 0.21
Validation 132 27 2 0 10% 0.65
PTPN11 SHP2 rs2301756 333–223A>G c___2978562_20 Exploration 131 30 0 0 9% 0.19
Validation 128 30 3 0 11% 0.43
ZAP70 ZAP70 rs13420683 −21–4127C>A c___1278468_10 Exploration 89 55 13 4 26% 0.29
Validation 88 51 20 2 29% 0.007
IFNG IFNγ rs2069718 367–895C>T c__15799728_10 Exploration 57 74 30 0 42% 0.49
Validation 55 74 30 2 42% 0.57
rs2069705 −1616T>C c__15944115_20 Exploration 72 70 19 0 34% 0.75
Validation 73 65 23 0 34% 0.18
WT wildtype, HET heterozygous, HVAR homozygous variant, MAF minor allele frequency, HWE Hardy–Weinberg equilibrium. a If <0.05 not consistent with HWE
Table 2. Patient characteristics at baseline
Number of patients (n
= 161; exploration
cohort)
Number of patients
(n= 161; validation
cohort)
Gender
Male 108 (67%) 94 (58%)
Female 53 (33%) 67 (42%)
Age at start (years)
Mean (±SD) 64 (±8.1) 65 (±9.1)
WHO performance status
0 26 (16%) 28 (17%)
1 95 (59%) 93 (58%)
2 2 (1%) 5 (3%)
3 1 (1%) 0 (0%)
Unknown 37 (23%) 35 (22%)
Primary lung tumour
Adenocarcinoma 97 (60%) 101 (63%)
Squamous cell
carcinoma
47 (29%) 49 (30%)
Great cell carcinoma 15 (9%) 7 (4%)
Unspeciﬁed 2 (1%) 4 (3%)
Number of pre-treatment lines
0 1 (1%) 0 (0%)
1 104 (65%) 113 (70%)
2 44 (27%) 38 (24%)
>2 12 (7%) 10 (6%)
Ethnicity
Caucasian 152 (94%) 156 (97%)
Other 4 (3%) 1 (1%)
Unknown 5 (3%) 4 (3%)
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(n= 46; 14%) occurred most frequently. Treatment-related grade
≥3 toxicities occurred in 23 patients (7%). Any grade treatment-
related adverse events occurred in 181 patients (56%; Supple-
mentary Table S2).
Eighty patients (25%) required oral or intravenous steroids
during nivolumab treatment. Thirty patients (9%) temporarily
interrupted nivolumab treatment because of toxicities, whereas
eleven patients (3%) had to permanently stop treatment because
of toxicities.
Treatment details
At the end of the data collection period, 150 patients (47%) were
still being treated with nivolumab. A total of 42 patients (13%)
stopped because of clinical deterioration, 108 patients (34%)
stopped after progressive disease (assessed by the treating
clinician), eleven patients (3%) stopped because of treatment-
related toxicities and ten patients (3%) stopped because of other
reasons, i.e., due to patients’ request (n= 5), sudden death (n= 4)
or a non-measurable lesion after re-evaluation of the baseline CT-
scan (n= 1). Twenty-three patients (7%) were lost to follow-up.
Association of SNPs with toxicity during nivolumab treatment
All outcomes of the exploration cohort that occurred in a sufﬁcient
number of patients for univariable analysis are shown in
Supplementary Table S3. Those outcomes with an association of
p < 0.1 in relation to the concerning SNP are described in Table 4.
The PTPN11 333–223A>G and PDCD1 *889G>A SNPs were only
tested in a dominant model since the number of homozygous
mutant patients was too low for reliable analysis. Since skin
toxicity, rheumatological toxicity, any grade ≥3 toxicity, treatment
related grade ≥3 toxicity, and temporary stop caused by toxicity
occurred in an insufﬁcient number of patients for reliable
multivariable analysis, these outcomes were only analysed
univariably. Diarrhea, elevated bilirubin, hepatitis, pneumonitis,
neuropathy, colitis and permanent stop caused by toxicity were
ineligible for univariable analysis. Decreased renal clearance
(≥grade 2), elevated transaminases, hypothyroidism or hyperthyr-
oidism and treatment-related adverse events (any grade) were
studied in multivariable analyses.
In the exploration cohort, homozygous variant patients for
PDCD1 804C>T had decreased odds for developing any grade
treatment-related adverse events (OR 0.4; 95% CI 0.2–1.0; p=
0.039). At least one variant allele at PTPN11 333–223A>G was
associated with increased odds for elevated transaminases (OR
2.4; 95% CI 1.1–5.5; p= 0.036). The relationship between
hypothyroidism or hyperthyroidism and PTPN11 333–223A>G in
univariable analysis did not hold in multivariable analysis (OR 0.4;
95% CI 0.2–1.0; p= 0.052). Of the endpoints that could only be
analysed univariably due to the number of patients, IFNG
−1616T>C was associated with rheumatological toxicity (OR 6.0;
95% CI 1.5–23.9; p= 0.019).
Associations between SNPs and endpoints that showed
signiﬁcance when tested in the exploration cohort, were re-
tested in the validation cohort of which results are shown in
Table 5. Since the associations between PTPN11 333–223A>G and
elevated transaminases (OR 1.509; 95% CI 0.690–3.300; p= 0.301),
and between PDCD1 804C>T and any grade treatment-related
adverse events (OR 0.923; 95% CI 0.449–1.899; p= 0.828) had p-
values > 0.1, these were not considered for multivariable analysis
in the validation cohort. Furthermore, the above described
association between IFNG -1616T>C and rheumatological toxicity
in univariable analysis did not hold in the validation cohort (OR
0.5; 95% CI 0.1–3.9; p= 0.695).
DISCUSSION
Although this is—to the best of our knowledge—the largest
pharmacogenetic pathway analysis in nivolumab treated NSCLC
patients so far, we could not validate SNPs of the PD-1 or PD-1-
related genes relevant for toxicity. Nonetheless, in the exploration
cohort, the TT genotype in the PDCD1 804C>T SNP (rs2227981)
was associated with less nivolumab related toxicity. Moreover, at
least one G allele in the PTPN11 333–223A>G SNP (rs2301756) was
associated with an increased risk for developing elevated
transaminases. Also, in univariable analysis, homozygous mutant
patients for the IFNG -1616T>C SNP had higher odds for
developing rheumatological toxicity. However, all ﬁndings could
not be replicated in the validation cohort.
Interestingly, a variant allele of PDCD1 804C>T has previously
been associated with susceptibility for ankylosing spondylitis and
type I diabetes.14 Possibly, this could be related to a decreased
activity proﬁle of the PD-1 pathway in patients harboring this SNP,
and these patients may therefore experience less inhibition of T
cell activation (Fig. 1). It may seem paradoxical that harboring two
variant alleles in the rs2227981 SNP is associated with less toxicity
in the exploration cohort, whereas earlier ﬁndings relate it to a
higher incidence of auto-immune related events. Speculating on
this, it could be that patients with the variant allele already have
less PD-1-mediated T cell inhibition, which may make this
pathway less susceptible to blockade by nivolumab. Conse-
quently, these patients may experience fewer treatment-related
toxicities than wildtype patients.
Our ﬁnding in the exploration cohort that patients with at least
one variant allele in the rs2301756 SNP have an increased risk for
developing elevated transaminases is in line with earlier studies:
the variant allele has previously been associated with
Table 3. Frequencies of toxicity endpoints corrected for pre-existence
Number of patients
(n= 161; exploration
cohort)
Number of
patients (n= 161;
validation cohort)
Any grade toxicity
Diarrhea 6 (4%) 7 (4%)
Skin toxicity 23 (14%) 23 (14%)
Elevated transaminases 50 (31%) 56 (35%)
Elevated bilirubin 7 (4%) 7 (4%)
Hepatitis 6 (4%) 2 (1%)
Hypothyroidism or
hyperthyroidism
64 (40%) 65 (40%)
Pneumonitis/Interstitial
lung disease
8 (5%) 8 (5%)
Colitis 2 (1%) 4 (3%)
Rheumatological
toxicity
10 (6%) 13 (8%)
Hypophysitis 1 (1%) 1 (1%)
Treatment-related
toxicity
96 (60%) 85 (53%)
Other outcomes
Decreased renal
clearance grade ≥2
28 (17%) 41 (26%)
Any grade 3 or higher
toxicity
24 (15%) 26 (16%)
Any grade 3 or higher
treatment-related
toxicity
14 (9%) 9 (6%)
Steroid use 42 (26%) 38 (24%)
Treatment stop caused by toxicity
Temporary interruption 15 (9%) 15 (9%)
Deﬁnitive
discontinuation
6 (4%) 5 (3%)
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susceptibility for ulcerative colitis in the Japanese population18
and with an increased risk for gastric atrophy after H. Pylori
infection,19 possibly caused by chronic inﬂammation. Our ﬁnding
supports the notion that genetic variants in the SHP2 gene
(PTPN11) prevent T cell suppression and do result in stronger T cell
reactions, in particular when there is additional inhibition of PD-1
via nivolumab treatment. Speculating on the underlying biological
mechanism, we argue that reduced SHP2 activity—in case of the
above-mentioned SNP—results in less de-phosphorylation (and
thereby de-activation) of its targets ZAP-70 and PI3K. As such, the
‘brake’ on proximal TCR-mediated signalling as well as more distal
PI3K signalling is relieved, which then results in enhanced T cell
activation (see Fig. 1).
In addition, the earlier reported ﬁnding between SNPs in IFNG
with systemic lupus erthythaematosis17 corresponds with our
ﬁnding in the exploration cohort, in which this SNP is associated
with rheumatological toxicities. The rs2069718 SNP in IFNG, and
the rs10204525 SNP in PDCD1, located on two genes that affect
each other’s expression according to a negative feedback loop,
were not associated with outcomes in both cohorts, possibly due
to the inﬂuence of other adjacent pathways related to IFNγ and
PD-1. We did not explore these adjacent pathways in the current
analysis, however, this research is part of ongoing work.
The explorative nature of this study and the retrospective data
collection may result in a slightly different low-grade toxicity
proﬁle than reported previously.23 Nevertheless, the clinically most
relevant endpoints, i.e., any grade ≥3 toxicity and treatment-
related grade ≥3 toxicity, are unlikely to be underrepresented in
this study as the median follow-up time (>4 months) exceeds the
previously described expected time for toxicities to occur.24 In fact
an endpoint such as treatment-related adverse events eliminates
distortion of the association between a SNP and an endpoint by
excluding adverse events that could be a consequence of other
factors, such as disease progression. Furthermore, some end-
points, e.g., colitis, occurred too infrequent to be assessed in
multivariable analysis, which requires about ten patients per
assessed variable.22 The cutoff date resulted in a relatively short
follow-up time in a small number of patients in both cohorts (n=
13 versus n= 12, respectively). However, earlier trials described
that most relatively frequent adverse events occur during the
ﬁrst few weeks of treatment, such as skin, gastrointestinal, and
hepatic toxicities.25 Therefore, we expect that inclusion of the
concerning patients had a negligible effect on most important
endpoints.
Associations between SNPs and survival are also important,
since predictive biomarkers for survival are currently lacking. As
the survival data are not mature enough yet, we will assess these
associations once the data allow us to. Although germline
genetics might seem logical biomarkers for general systemic
effects, such as adverse events, and although (local) antitumour T
cell effects are also affected by somatic mutations and mutational
load,26 prior treatment, and possibly even the microbiome,27 SNPs
studied here might provide additional predictive information to
these other biomarkers.
Despite our above stated explanations for the ﬁndings in the
exploration cohort, it should be emphasised that they could not
be validated, even though the distribution of events per genotype
was comparable between the two cohorts for the relationships
Table 4. Association between SNPs with p < 0.1 in the univariable analysis and endpoints (exploration cohort)
Endpoint Factor Genotype Univariable Multivariable
OR (95% CI) p-value OR (95% CI) p-value
Decreased renal clearance (≥grade 2) Age 1.056 (0.999–1.116) 0.056
Gender (f. vs. m.) 1.364 (0.555–3.350) 0.498
PDCD1 804C>T CC → CT → TT a 1.631 (0.917–2.903) 0.096b 1.545 (0.864–2.763) 0.142
Elevated transaminases (any grade) Age 1.010 (0.967–1.055) 0.649
Gender (f. vs. m.) 1.741 (0.841–3.604) 0.135
PTPN11 333–223A>G GG+AG vs. AA 2.309 (1.024–5.208) 0.041c 2.421 (1.061–5.523) 0.036
Hypothyroidism or hyperthyroidism (any
grade)
Age 0.989 (0.950–1.030) 0.598
Gender (f. vs. m.) 1.158 (0.579–2.315) 0.678
PTPN11 333–223A>G GG+AG vs. AA 0.395 (0.158–0.985) 0.061d 0.403 (0.161–1.007) 0.052
Treatment-related adverse events (any grade) Age 1.007 (0.967–1.049) 0.738
Gender (f. vs. m.) 1.234 (0.609–2.498) 0.560
PDCD1 804C>T TT vs. CC+ CT 0.454 (0.211–0.978) 0.041c 0.440 (0.202–0.958) 0.039
Rheumatological toxicity (any grade) IFNG -1616T>Ce CC vs. TT+ TC 6.044 (1.531–23.857) 0.019d
OR odds ratio, CI conﬁdence interval, f. vs. m. females versus males. aAdditive model was used. bLogistic regression was used. cChi-square test was used.
dFisher’s Exact test was used. eOnly tested univariably due to the number of events
Table 5. Association between SNPs and endpoints with a signiﬁcant correlation in the exploration cohort
Endpoint Factor Genotype Univariable
OR (95% CI) p-value
Elevated transaminases (any grade) PTPN11 333–223A>G GG+ AG vs. AA 1.509 (0.690–3.300) 0.301a
Treatment-related adverse events (any grade) PDCD1 804C>T TT vs. CC+ CT 0.923 (0.449–1.899) 0.828a
Rheumatological toxicity (any grade) IFNG -1616T>C CC vs. TT+ TC 0.477 (0.059–3.857) 0.695b
OR odds ratio, CI conﬁdence interval. aχ2 test was used. bFisher’s Exact test was used
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between elevated transaminases and the SNP in PTPN11 and
between any grade treatment-related adverse events and the SNP
in PDCD1 804. However, in the validation cohort, there was one
patient with a rheumatological toxicity in the homozygous mutant
group for the IFNG -1616T>C SNP, which could explain the
contradictory ﬁnding with the exploration cohort.
The current genotyping effort should not be considered
comprehensive. Even though it is likely that other factors than
germline genetics may contribute to the occurrence of adverse
events, our study provides a starting point from where other
genes, or even other SNPs in the investigated genes, could be
investigated towards future biomarker development for anti-PD-1
treatment outcomes.
As mentioned, main limitations of this analysis arise from the
retrospective data collection. Therefore, subtle adverse events
(grade 2 or less) may not have been mentioned by the
treating physician, or its pre-existence may not have been
noticed. Also, the distinction between treatment-related toxi-
cities or adverse events caused by other sources may be unclear
for some lower-grade and general toxicities. Moreover, since
some toxicities occur only in a very small proportion of
immunotherapy treated patients, these outcomes had to be
excluded from the analysis. Finally, this analysis was restricted
to a limited proportion of the PD-1 pathway and its associated
genes and polymorphisms.
In conclusion, this study shows that future biomarker research for
nivolumab treatment outcomes can and should embrace germline
genetics. However, it is unlikely that the investigated SNPs have a
clinical implication in the prediction of toxicity in NSCLC patients
treated with nivolumab. Considering underlying biological mechan-
isms, these SNP probably have no relevance in patients with other
tumour types and patients receiving other anti-PD-1 agents. The
reported lack of associations facilitates further research in biomarker
development for checkpoint inhibitor treatments.
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